A retrospective study assessing the impact of Defibrotide in the prevention of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
Latest Information Update: 19 Jan 2022
Price :
$35 *
At a glance
- Drugs Defibrotide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Jan 2022 New trial record
- 11 Jan 2022 Results published in the Annals of Pharmacotherapy